WallStSmart

Boston Scientific Corp (BSX)vsHeart Test Laboratories Inc. Common Stock (HSCS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 477286332% more annual revenue ($20.61B vs $4,319). BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

HSCS

Avoid

13

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 2.5
Piotroski: 2/9Altman Z: -23.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-23.2%)

Margin of Safety

-23.2%

Fair Value

$37.36

Current Price

$45.98

$8.62 premium

UndervaluedFair: $37.36Overvalued

Intrinsic value data unavailable for HSCS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$63.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.548/10

Growing faster than its price suggests

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

HSCS1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

HSCS4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.86M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : HSCS

The strongest argument for HSCS centers on Price/Book.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : HSCS

The primary concerns for HSCS are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 17.41 is elevated, increasing financial risk.

Key Dynamics to Monitor

BSX profiles as a mature stock while HSCS is a value play — different risk/reward profiles.

HSCS carries more volatility with a beta of 1.79 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 13/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Heart Test Laboratories Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company is headquartered in Southlake, Texas.

Visit Website →

Want to dig deeper into these stocks?